Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prometheus’ Lotronex REMS Could Lose Its Sticker Verification Requirement

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA seeks advisory committee input on options for revising the irritable bowel syndrome drug’s Risk Evaluation and Mitigation Strategy, including eliminating a requirement for paper-based prescriptions and integrating the REMS into electronic pharmacy management systems.

You may also be interested in...

REMS Standardization Gets Boost From Lotronex Sticker Review

FDA’s Drug Safety and Risk Management Advisory Committee endorses replacing paper-based verification system for the irritable bowel syndrome drug with an electronically integrated process that the agency seems to favor; the electronic system currently is used in the REMS for transmucosal immediate-release fentanyl products.

Lotronex REMS’ Verification Process Should Be Electronic, FDA Panel Says

Drug Safety and Risk Management Advisory Committee overwhelmingly favors elimination of paper-based sticker system to verify prescriber enrollment and documentation of safe use conditions under Prometheus’ REMS for the irritable bowel syndrome drug.

Everything REMS Under The Sun: FDA Lays Out Ambitious PDUFA V Meeting Agenda

The struggles that industry and FDA face when trying to best standardize and evaluate REMS are illustrated by the dozens of topics jammed into the two-day meeting.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts